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 Abstract 
Microspheres as a drug delivery system hold great promise in reaching the goal of controlled drug delivery as well 
as site specific delivery. In the last few decades, scientific and technological advancements have been made in the research 
and development of radio labeled microspheres. These are used successfully for the treatment of various cancers and 
tumors. Since response to chemotherapy and external radiotherapy is not so effective and hazardous too, so an alternative to 
this is internal radiation therapy. These radio labeled microspheres are very stable and have a proven efficacy in the field of 
primary as well as metastatic cancers. Radioactive microspheres can be selectively targeted to various tumors without 
undue radiation to the non tumorous tissues. The radioactive microspheres are injected to halt tumor growth via the blood 
supply, thereby enabling surgical removal once the tumor size decreases. This review provides an outlook to various 
aspects of radioactive microspheres and their role in treatment of various tumors and cancers. 
Keywords: Radioactive microspheres, Radionuclide, Radiation therapy. 
1. Introduction  
In connection with aim of maximizing the 
bioavailability of conventional drugs with minimum side 
effects, new drug delivery systems continue to attract much 
attention. Such systems include microspheres, liposomes, 
nanospheres etc. These drug delivery systems lend 
themselves to parenteral administration and are useful for 
sustained release of drugs. There is also the possibility of 
directing the drug to an appropriate organ or target site 
within the body through these colloidal drug delivery 
systems. Microspheres form the basis of colloidal drug 
delivery systems; hence they have received a great impetus. 
Microspheres are solid, approximately spherical particles 
ranging from 1 to 1000 mm in size. They are made of 
polymeric, waxy or other protective materials that include 
biodegradable synthetic polymers and modified natural 
products such as starches, proteins, fats and waxes.  
The natural polymers include albumin and gelatin 
whereas the synthetic polymers include polylactic acid, 
polyglycolic acid etc. In the past few decades, microspheres 
have been extensively exploited for therapeutic purposes, 
especially for the treatment of various cancers. This 
approach involves the use of microspheres labeled with 
suitable radionuclides or isotopes instead of a drug. For 
therapeutic purposes, radiolabeled microspheres are used 
for radioembolization therapy of tumors and cancers. 
Radioactive microspheres have an advantage of delivering 
high concentration of radioactivity to the target area without 
causing any damage to the surrounding tissues and organs. 
Following administration, these microspheres get entrapped 
in the web of small blood vessels feeding a tumor and thus 
deliver the required concentration of radioactivity at the 
target site. The radioactivity is never released from the 
microspheres and acts from within. The effective treatment 
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range is up to 90 mm for alpha emitters, for beta emitters 
the range is not more than 12 mm and for gamma emitters 
the range is up to several centimeters. In chemotherapeutic 
approach, the drugs have to be withdrawn even before the 
complete removal of the tumor, which finally leads to 
revival of tumor tissue. Withdrawal problems are not there 
in the case of radioactive microspheres and thus the use of 
radioactive microspheres shows better chances for complete 
eradication of tumors. Another important advantage of 
radioactive microspheres is patient compliance since the 
radioactivity dose persists at a target site for at least four 
weeks and high concentrations can be achieved at the target 
site.[1-5] 
 
2. Types of Radioactive Microsphere  
2.1 Therapeutic Radioactive Microspheres  
Many radio labeled microspheres are appropriate 
for therapy once the encapsulated diagnostic radioisotope 
has been exchanged for a therapeutic one from the α- or β-
emitter group. Typical uses in the last 20 to 40 years 
include local applications for the treatment of rheumatoid 
arthritis, liver tumors and cystic brain tumors. However, 
their use remains experimental because of smaller than 
expected target uptake, unwanted toxicity and insufficient 
treatment effects that have resulted from radio chemical 
instability and suboptimal biodistribution of the 
radiopharmaceutical. In addition there exists a general 
negative attitude towards the use of radioactive substances 
in spite of proven superior results of many radiation 
therapies. Few therapeutic applications of radioactive 
microspheres are tabulated as follow [6-7]: 
 
Table 1: Therapeutic applications of microspheres 
Type of radioactive 
microspheres 
Applications 
90Y-glass microspheres, 
186Re/188Re-glass 
microspheres 
Radioembolisation of liver 
and spleen 
Tumors 
35S-colloid, 90Y-resin 
microspheres, 
169Er.citrate 
Radiosynovectomy of 
arthritis joints 
90Y-labeled poly(lactic acid) 
microspheres, 
211At-microspheres, 212Pb-
sulfur colloid 
Local radiotherapy 
Chromium 32P-phosphate, 90Y-
silicate 
Intracavity treatment 
 
2.2 Diagnostic radioactive microspheres  
Diagnostic studies with radiopharmaceuticals 
include dynamic and static imaging and in vivo function 
tests. Dynamic imaging provides information about the Bio 
distribution and pharmacokinetics of drugs in organs. 
Performed with a γ-camera, dynamic studies are generally 
carried over a preset length of time and provide clues to the 
functioning of the organ being examined. The first such 
microspheres in clinical use were red and white blood cells, 
which were taken from a patient, labelled with 
111
In or 
51
Cr, 
and then re-injected. Red blood cells labelled with 
51
Cr 
commonly used for the measurement of red blood cell mass 
and imaging of the spleen. Another common application of 
radiolabelled red blood cells is the accurate determination 
of total systemic arterial flow or venous return, as well as 
for blood flow determination within specific organs. 
Various diagnostic applications of radioactive microspheres 
are as follows [8-9]: 
 
Table 2: Diagnostic applications of radioactive 
microspheres 
Type of radioactive 
microspheres 
Applications 
111In or 51Cr-labelled red blood 
cells 
Gated blood pool study 
111In-labeled platelets, 99mTc-
sulfur colloid 
Thrombus imaging in deep 
vein 
thrombosis 
Polystyrene microspheres 
labeled with γ- 
emitters 141Ce, 57Co, 114mIn, 
85Sr, 51Cr 
Blood flow measurements 
3H, 14C-labelled microspheres 
141Ce-polystyrene microspheres 
Investigation of 
biodistribution and 
fate of drug loaded 
microspheres 
99mTc-impregnated carbon 
particles 
99mTc-macro aggregated human 
serum albumin 
Lung scintigraphy 
99mTc-macro aggregated human 
serum 
Albumin 
Radioembolisation 
99mTc-macro aggregated human 
serum 
albumin 
Liver and spleen imaging 
99mTc-sulfur colloid 
99mTc-antimony sulfide colloid 
Bone marrow imaging 
 
 
Figure 1: Radioactive protein kinase assay 
 
 
 
Asma Gangat et al / A Review: Radioactive Microspheres as a Theranostics                                                           59 
IJAP (2018) 07 (07)                                                                                                                                          www.ssjournals.com 
3. Selection of radionuclide  
The choice of radionuclide is determined by the 
organ/tissue to be treated. Absorption, distribution, 
metabolism and excretion of radiopharmaceuticals can be 
followed by scintigraphy. Depending upon their use, they 
may be administered orally or by injection. The uses of 
radionuclides for the treatment of various types of cancers 
have been an effective alternative to other therapies such as 
chemotherapy and external radiation therapy. 
General requirements for the selection of 
radionuclides include lack of toxicity, ease of elimination 
from the body, small size to allow intravenous injection, 
sufficient radiation spectrum, simple labeling procedures 
and no leakage of isotope from particles surface. Most 
routinely used radiopharmaceuticals are technetium-
99m
 
(
99m
Tc) labeled compounds that are prepared by adding 
sodium pertechnetate to nonradioactive lyophilized 
ingredients supplied in a “kit” form suitable for 
administration. 
99m
Tc has ideal physical characteristics. It 
emits only gamma radiation in the range of a gamma 
camera detector. Its half-life of 6 h limits the radiation dose 
to the patient. Other important radioisotopes are 
90
Y 
(Yttrium), 
188
Re (Rhenium) and 
166
Ho (Holmium). [10-12] 
3.1 Yttrium [10-12] 
90
Y is the decay product of strontium-90. Also 
produced by 
89
Y(n, g). 
90
Y is a high energy pure beta 
emitting isotope with a half life of 64.1 h. The maximum 
energy of beta particles is 2.27 MeV and the maximum 
range of emission in tissue is 11 mm. 
90
Y has two major 
disadvantages. Firstly, a long neutron activation time (> 2 
weeks) is needed to attain therapeutic activities of yttrium. 
Secondly, Bio distribution of 
90
Y loaded microspheres 
cannot be directly determined in clinical trials since 
90
Y is a 
pure beta emitter and does not produce imageable gamma 
rays. 
3.2 Rhenium [10-12] 
The radioisotopes of rhenium 
188
Re and 
186
Re have 
unique physical properties that make them attractive for 
radiotherapy. 
188
Re has a half life of 3.78 days with 
maximum beta energy of 1.07 MeV whereas 
186
Re has a 
shorter half life of 17 h and maximum beta energy of 2.12 
MeV. Both isotopes have imageable gamma rays. 
3.3 Holmium [10-12] 
166
Ho is produced by neutron capture of 
165
Ho 
which has a natural abundance of 100%. 
166
Ho has a half-
life of 26.83 h and decays by emission of 1.855 MeV and 
1.776 MeV maximum energy beta particles. Its physical 
properties are suitable for plenty of medical applications, 
for example, skin and hepatic malignancies, rheumatoid 
arthritis etc. 
 
3.4 Radioactive microspheres for radiation therapy [13-
15] 
An early approach in radiation therapy involved 
the use of yttrium oxide powder suspended in a viscous 
media. Yttrium was selected as it emits nearly 100% beta 
radiation. But the major disadvantage of yttrium oxide 
powder is its high density (5.01 g/cm
3
) and irregular 
particle size. The high density makes it difficult to suspend 
the particles in the medium and this accelerates their 
tendency to settle in the blood stream prior to reaching the 
tumor as desired. Sharp corners and edges of the particles 
irritate the surrounding tissues and interfere with uniform 
distribution. In recent applications, microspheres 
comprising of glass material, polymer or resin are being 
used. Depending upon the application it is desirable to link 
the microspheres with a suitable radionuclide. The stability 
of these microspheres is such that they do not release a 
significant amount of radiation emitting material into the 
surrounding tissues. The suitability of the microspheres for 
radiation therapy is based upon the properties of targeted 
delivery of radioactivity, uniform distribution of radioactive 
material throughout the microsphere material, easy 
activation by neutron irradiation of microspheres bearing a 
suitable isotope, low leakage or leaching of radioactive 
material, suitability for parenteral administration, uniform 
size distribution and easy labeling. The three major 
microsphere materials viz glass-based, resin-based and 
polymer-based are preferably used for microsphere 
preparation.  
3.5 Glass microspheres [16-20] 
The glass microspheres are incredibly small (20–
30 mm) in size. Glass has minimum radionuclide impurities 
and is non-toxic, non-resistant to radiation damage. Glass 
microspheres can be easily prepared in uniform sizes and 
easily administered. Each injection contains five to ten 
million microspheres for delivering radioactive material to 
the desired target. The manufacturing process was 
described by Ehrhardt and Day [9]. A beta-emitting 
radioisotope was chemically dissolved in and distributed 
uniformly throughout the glass material. The glass based 
materials used were aluminosilicate, magnesium 
aluminosilicate, lithium silicate, potassium silicate etc. 
containing 166Ho, 186Re, 90Y as radioisotopes. Glass has 
many advantages over nonglass materials: it confers 
targeted delivery of radioactivity to the tumor site; 
sufficient dosage of radiation and ease in the preparation of 
glass microspheres. But the major drawback of glass 
microspheres is their high density (3.29 g/ml) and non-
biodegradability [24].  
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The high density results in side effects due to 
premature intravenous settling and falling back into the 
gastroduodenum. In radiotherapy, glass microspheres 
labeled with radionuclide have been used. This eliminates 
the problem of leaching of radionuclide material. More 
recently, new yttrium based glass microspheres in which 
the leaching problem has been eliminated have been 
developed under the trade name “Theraspheres”. 
Theraspheres with a diameter of 15–30 mm contain a stable 
89
Y isotope which is activated by neutron bombardment in a 
nuclear reactor to 
90
Y. Houle et al [18], used 
90
Y glass 
microspheres in the treatment of hepatocellular carcinoma 
(HCC). The 
90
Y microspheres were injected via a hepatic 
artery catheter. No toxicity was observed for doses between 
50 and 100 Gy to the liver and up to
 320
Gy to the tumor 
itself. Thus as desired, the large absorbed doses of internal 
radiation can be safely delivered to hepatic tumors if the 
presence of extrahepatic shunting is excluded. Radioactive 
rhenium glass microspheres are an alternative to yttrium 
glass microspheres as the production of 
90
Y is time 
consuming and include costly neutron activation in a 
nuclear reactor. Rhenium microspheres are used for the in 
vivo irradiation of diseased organs in the body, for 
example, malignant tumors and the inflammed synovium of 
the joints. The radioactive microspheres are directly 
injected into the synovial sac where they deliver enough 
radiation (
100
Gy) to destroy the inflammed lining of the 
diseased synovial membrane. 
3.6 Polymer based microspheres [16-20] 
Polymers are used as vehicles for the 
immobilization and local delivery of radionuclides or 
radiopharmaceuticals. Radionuclides are either physically 
adsorbed or chemically linked to a polymeric surface. 
Polymer based microspheres have many advantages over 
glass microspheres which include biodegradability, 
biocompatibility, systemic and controlled release of 
radionuclide from polymer etc. This provides a way to 
control local dosage of radiation without the need for 
physical removal of the implanted radionuclide. The best 
known biodegradable polymers which are hydrolysed 
without enzymes and metabolized by the body are 
polylactic acid, polyglycolic acid and their copolymers poly 
(lactic-co-glycolic acid). Preferred radioisotopes are those 
which have a particle range in tissue according to the tissue 
layer which is to be targeted. For example beta particles 
emitting radioisotopes like carbon-14, sulphur-35 and 
phosphorous-33 will be absorbed in the first 70 microns of 
tissue whereas more energetic beta particles emitting the 
radioisotope phosphorous-32 have a longer range of about a 
centimeter and can be used to treat thicker tumors [20]. 
Polymeric microspheres are prepared by the solvent 
evaporation technique. The polymer is dissolved in a 
suitable volatile solvent and dispersed in a continuous 
medium using a stabilizing agent, Controlled evaporation of 
solvent results in the formation of solid microspheres. The 
solvent evaporation method has been used for the 
preparation of polylactic acid microspheres containing 
166
Ho, 
90
Y, 
186
Re as radioisotopes [19]. Radioactive 
166
Ho 
loaded polylactic acid microspheres were prepared by 
Mumper et al [23]. Holmium-165-acetylacetonate 
(HoAcAc) and polylactic acid were dissolved in chloroform 
and the solution was added to polyvinyl alcohol solution. 
The final solution was stirred until the evaporation of the 
solvent. Microspheres were graded and collected according 
to size. These microspheres were recently tested for the 
treatment of hepatic malignancies in rabbits. The bio-
distribution and histological analysis confirmed that 
radioactive microspheres got heterogeneously distributed 
over the liver and accumulated preferentially in the tumor 
area. It was demonstrated that 
166
Ho polylactic acid 
microspheres were the promising systems for the liver 
tumor treatment [26]. Van et al used 
166
Ho loaded 
polylactic acid microspheres for radio-embolization of 
unresectable head and neck cancer in rabbits. Complete 
tumor remissions were obtained in 79% of rabbits. Over 
95% of the microspheres retained in the tumors indicated 
that polymeric microspheres could be used for the 
embolization of tumors. Magnetic polylactic acid 
microspheres loaded with a beta emitting radioisotope like 
90
Y were made by Hafeli et al[14]. It was reported that 
magnetic microspheres could be selectively delivered to the 
target site after incorporating 10% Fe3O4 (magnetite). 
Magnetic microspheres get slowly hydrolysed into lactic 
acid after the complete decay of radioactivity. These 
microspheres were used for intracavital tumor therapy. 
Experiments showed a twelve fold increase in the activity 
in tumor with a directional magnet fixed over the tumor. 
3.7 Albumin based microspheres [16-20]
 
Albumin is a type of globular protein and is 
present in blood and tissues. When human serum albumin is 
to be used for organ imaging, it is denatured to produce 
albumin aggregates and then selectively sieved to obtain 
desired particle size. When used diagnostically, albumin is 
combined with a radioisotope such as 
99
Tc, 
131
I. Albumin 
microspheres received considerable attention because of 
their biodegradability, biocompatibility, non-antigenicity 
and organ specific targeting properties. Various methods 
have been reported for the preparation of albumin 
microspheres. Microspheres of ovalbumin (OVA), prepared 
by emulsifying an aqueous solution of albumin in soybean 
oil have been labeled with technetium after reduction by 
thiosulfate or stannous chloride. Currently 
99
mTc 
microspheres of human serum albumin are widely used for 
lung scanning [28]. More recently 
99m
Tc human serum 
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albumin microspheres have been used successfully for the 
treatment and assessment of the radiation induced gastritis, 
pneumonitis, lungs shunting etc. The tumor to normal tissue 
(T/N) ratio determines how safe and effective the treatment 
is Ho et al[17]. This determination of tumor to normal 
tissue ratio by simulation with 
99m
Tc albumin microspheres 
is recommended before internal radiation therapy. Lau et 
al[20] in 1994 used 
99m
Tc macro aggregated albumin 
(MAA) to assess the vascularity of liver metastasis and to 
predict the tumor to normal (T/N) tissue ratio in selective 
internal radiation therapy. It was estimated that if T/N ratio 
is not less than 2, then selective internal radiation therapy 
should be followed. This allowed the radioactive dose to be 
delivered to the tumor while keeping the radiation dose to 
the nontumorous liver within the tolerance limit. In 2000 
Wunderlich et al reported human serum albumin (HSA) 
microspheres labeled with 
188
Re for internal radiotherapy of 
tumors. These microspheres were uniform in size, with a 
mean diameter of 25 mm and were biocompatible and 
biodegradable. Intravenous injection in Wistar rats, using 
the lungs as a model for a well-perfused tumor, 
demonstrated sufficient in vivo stability. Yttrium was also 
used with human serum albumin for internal radiotherapy 
of lung tumors. Experiments were carried out in mice using 
90
Y macroaggregates of human serum albumin for whole 
lung irradiation. Based on its rapid clearance from the lung, 
it was suggested for internal radiotherapy. 
3.8 Resin based microspheres [16-20] 
Microspheres based on ion exchange resins are 
favoured for radioembolization due to lower density 
compared with glass, ease in labeling and their commercial 
availability. In comparison to polymers and glass, resin 
microspheres are suspended in physiological saline, thus 
avoiding any complications whereas ceramic microspheres 
must be suspended in either viscous or dense solutions. 
Zielinksi and Kasprzyk, prepared cation exchange resin 
microspheres labeled with 
32
P for radiation therapy of 
hepatic neoplasms. The maximum energy of the 
32
P beta 
particle was 1.71 MeV resulting in tissue penetration of 8 
mm thickness. The range was short enough to minimize 
unwanted irradiation to sensitive adjacent organs. 
Approximately 
15m
Ci of 
32
P labeled microspheres 
distributed uniformly in a 2100 g liver and delivered a dose 
of 5000 rads. 
99
Tc labeled anion exchange resin (AG1-X8) 
microspheres were also prepared and studied. Microspheres 
of AG1-X8 (60 mm diameter) were mixed with 5–200 mCi 
of 99Tc pertechnetate in physiological saline. The labeled 
microspheres were washed with water, supernatant was 
removed and placed into an oven for 15 min (270
0
C). The 
99
Tc labeled microspheres were ultrasonically dispersed in 
saline. 
99
Tc radiopharmaceuticals are used routinely in 
nuclear medicine practice. Turner et al prepared 
microspheres by the addition of 
166
Ho-chloride to the cation 
exchange resin Aminex A- 5. A reproducible, nonuniform 
distribution of the 166 Homicrospheres throughout the liver 
was observed on scintigraphic images, following 
intrahepatic arterial administration in pigs. This predictable 
distribution allowed these investigators to determine the 
radiation absorbed dose and to define the administered 
activity required to provide a therapeutic dose. Aminex A-
27 was labeled with 188Re by adding 
188
Re-perrhenate and 
SnCl2 to vacuum dried resin particles by Wang et al. These 
188
Re labeled microspheres were injected by direct 
intratumoral injection into rats with hepatoma. In the 
treated group, survival over 60 days was better than in a 
control group. Campbell et al [5] investigated the 
microscopic distribution of microspheres in human liver 
following hepatic infusion of 32 mm resin microspheres 
labeled with 
90
Y as a treatment for a liver cancer with a 
diameter of 80 mm. The observed deposition patterns 
indicated that the vascular tumor periphery received much 
greater radiation doses from radioactive microspheres than 
both normal and the a vascular tumor centre. 
 
4. Applications of radioactive microspheres  
In the past few decades, radioactive microspheres 
are being exploited for therapeutic applications. But owing 
to their ability to deliver high concentrations of 
radioactivity to the target site without damaging normal 
surrounding tissues, they are extensively exploited for the 
treatment of cancer. 
The limited efficacy of current approaches to the 
treatment of cancer has reawakened interest in the use of 
radio labeled therapy which involves the use of radio 
labeled microspheres. Microspheres labeled with a 
radioactive isotope are injected directly into the diseased 
areas. External beam radiation requires about ten treatments 
over a period of 30 days to deliver a dose of 2000 to 2500 
rads. In contrast, radioactive microspheres safely deliver an 
average dose of 15000 rads in a single treatment with 
minimal damage to healthy surrounding tissues. Currently 
this novel approach is finding success in fighting different 
cancers viz. liver cancer, head and neck cancer, spleen 
cancer etc. [21-24] 
4.1 Applications in oncology [25,26] 
4.1.1 Treatment of liver metastases or secondary cancer 
Hepatic tumors derive most of their blood supply 
from the hepatic artery, whereas the non tumorous part of 
the liver gets 80% of its blood supply from the portal vein 
and only 20% from the hepatic artery. So most of the 
radioactive substances including microspheres injected 
through the hepatic artery are delivered to the tumor, giving 
a favourable uptake ratio of tumor to normal tissue (T/N). 
In early studies Grady [12] estimated the good objective 
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regression of cancers, improvement of symptoms and 
prolongation of life in seventeen of the twenty five patients 
treated by 
90
Y resin microspheres. Blanchard et al[3] 
carried out a study by injecting 
90
Y plastic microspheres (15 
mm diameter) into the hepatic artery of fifteen patients with 
liver metastases and one patient with hepatoma. The study 
revealed that there was reduction in tumor volume by more 
than 50% while the mean survival rate was 62 weeks. 
However there was gastric ulceration due to unintended 
infusion of the radio labeled microspheres into the gastric 
circulation. By measuring the radiation doses received by 
the tumor and the nontumorous liver parenchyma 
separately, it was found that non tumorous liver could 
tolerate more than 30 Gy which is currently considered the 
limit for whole liver irradiation using external beams 
without any evidence of radiation hepatitis. Based upon the 
observation that patients who received up to 138.9 Gy to 
the nontumorous liver did not develop radiation hepatitis, 
an arbitrary safety limit of 80 Gy to the normal liver 
delivered by 
90
Y microspheres was recommended [13]. 
Magnesium alumino borate glass microspheres containing 
radioactive rhenium were prepared and successfully used to 
treat liver tumors by radio embolization. The microspheres 
were made radioactive by neutron activation and then 
injected into the hepatic artery of sprague-dawley rats with 
one week old hepatoma. The bio-distribution studies 
showed a sevenfold increase of microsphere uptake by 
hepatoma as compared to healthy liver tissue. Tumor 
growth in the animals receiving radioactive microspheres 
was significantly lower than in the animals receiving 
nonradioactive microspheres. So it was concluded that 
radioactive rhenium microspheres were effective in slowing 
down or even diminishing liver tumor growth without 
altering hepatic enzyme levels [15]. Recently, 
biodegradable polylactic acid microspheres labeled with 
166
Ho have been manufactured for internal radiation therapy 
of hepatic tumors. Nijsen et al [25], investigated the 
therapeutic effects of 166Ho loaded polylactic acid 
microspheres in rabbits with liver tumors. Rabbits were 
divided into three groups as Sham treated rabbits (n ¼ 3), 
“cold” microspheres treated rabbits (n ¼ 3) and 166Ho 
microspheres treated rabbits. Biodistribution and 
histological analysis confirmed that radioactive 
microspheres got heterogeneously distributed over the liver 
and accumulated preferentially in the tumor area. Sham 
treated and cold microspheres treated rabbits showed an 
exponential tumor growth. The study demonstrated that 
166
Ho polylactic acid microspheres were the promising 
systems for liver tumor treatment. 
4.1.2 Treatment of hepatocellular carcinoma 
Encouraged by the results achieved in the case of 
liver metastases, the therapy was extended to patients with 
hepatocellular carcinoma. In the late 1960’s and early 
1970’s, 90Y labeled inert ceramic or resin microspheres 
were injected into hepatic arteries of patients at an 
estimated dose ranging from 50 to 200 Gy. Inspite of 
striking response and survival rates, complications arised 
due to unexpected leaching of yttrium from the surface of 
microspheres and due to subsequent uptake of free yttrium 
by the bone marrow which led to lethal myelosuppression 
and radiation hepatitis. Largely as a result of these 
complications interest in this approach declined until the 
late 1980’s. The recently developed 22 mm glass 
microspheres (Theraspheres1) incorporate 
89
Y oxide into a 
glass matrix from which yttrium is unable to leach out. 
Wollner et al found that injection of cold theraspheres to be 
well tolerated. Moreover microspheres did not appear in the 
bone-marrow causing no myelosuppression. Burton et al[4] 
demonstrated that pretreatment with angiotensin II 
increased the microspheres uptake by the tumor by 
threefold in rabbits with VX2 hepatoma and Walker 
carcinoma in rats. Accessibility of the microspheres to the 
central portion of the tumors had also increased. Earlier 
there were no reports on the effect of 
90
Y glass 
microspheres in the treatment of liver cancer via the portal 
vein. In 1993 Yan et al studied the administration of 
90
Y 
glass microspheres via the portal vein. It was concluded that 
90
Y glass microspheres were effective in the treatment of 
liver cancer. In the study, conducted by Wang et al, 
188
Re 
was used to label microspheres. The authors analysed the 
biodistribution and survival times after the intratumoral 
injection of 
188
Re microspheres into rats suffering from 
hepatoma. The bio distribution studies revealed that 
radioactivity in the tumor was very high while in all other 
organs it was quite low. In addition, it was concluded that 
direct injection of 
188
Re microspheres was extremely 
attractive as a therapeutic alternative in hepatoma patients. 
Hepatocellular carcinoma constitutes a difficult health 
challenge because of its poor prognosis and limited 
treatment options. UPCI (2002) reported a new treatment 
for inoperable primary liver cancer with Theraspheres1 
which appeared to be safe and effective for liver cancer 
patients. Recently a new attractive approach was suggested 
to selectively deliver therapeutic doses of radiation to 
hepatic tumors. In a recent study by Georgiades et al [10] 
90
Y microspheres were administered via the hepatic artery 
to patients with liver malignancies. This procedure provided 
a way of delivering radiation doses in excess of 100 Gy to 
the tumors by sparing the normal tissue. Carr et al[6] used 
90
Y glass microspheres for the treatment of unrespectable 
and transplantable advanced stage hepatocellular 
carcinoma. These 
90
Y labeled glass microspheres were 
delivered via the hepatic artery in 43 patients. It was 
observed that 27 out of 43 patients were evaluable for the 
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response and 12 patients had stable disease. From the study, 
it was estimated that Theraspheres1 appeared to be a 
promising, nontoxic and effective treatment for 
unresectable hepatocellular carcinoma. More recently in 
2003, Sarfaraz et al., administered 90Y microspheres via 
the hepatic artery to selectively deliver therapeutic doses of 
radiation to liver malignancies. This procedure allowed to 
deliver radiation absorbed doses in excess of 100 Gy to the 
tumors without significant liver toxicity. Microspheres were 
administered via a catheter placed into the hepatic artery. 
The actual radiation absorbed doses to tumors and normal 
liver tissue was calculated based on the 
99
mTc macro 
aggregated albumin study and computed tomography scans. 
As expected, the activity uptake within the liver was found 
to be highly non-uniform and a multi fold increase of 
uptake in tumor compared to nontumor tissue was 
observed. The radiation absorbed dose for tumor and liver 
were 402 Gy and 118 Gy, respectively. 
4.1.3 Bone tumor 
A traditional and definite method for bone tumor 
diagnosis is bone biopsy but this procedure has many risks 
and also increases the rate and extent of tumor cell 
metastases. An alternative to this traditional approach is the 
use of radioactive microspheres. In 1985, Robertson et al. 
Used radioactive microspheres of 15 mm (diameter) to 
explore the spread of tumor cells from the distal femur into 
the lymphatic system, venous drainage and local tissue. 
Radioactive microspheres have been used for the study of 
bone microcirculation in aseptic osteonecrosis of the 
femoral head. With the injection of radioactive 
microspheres it was possible to show that aseptic necrosis 
begins with global ischaemia and is followed by incomplete 
revascularization leaving a necrotic area. On the border 
between the two areas hypervascularity produced a zone of 
fragility where micro fractures developed with detachment 
of a sequestrum. 
4.1.4 Head and neck cancer 
The role of intra-arterial radioisotope therapy in 
the treatment of head and neck cancer was studied. From an 
experimental study in rabbits, it was found that 166Ho 
loaded polylactic acid microspheres are promising 
candidates for studies on radio embolization of 
unrespectable head and neck cancer. The effects on tumor 
growth, retaining efficiency of microspheres in primary 
tumor and the excretion of free 166 Ho were analysed by 
embolizing the radioactive Ho-labeled PLA microspheres 
into rabbits with VX2 squamous cell carcinoma. Complete 
tumor remission was obtained in 79% of the rabbits 
following embolization with radioactive microspheres. 
Over 95% of the microspheres were retained in the tumor. 
Dextran hydrogel microspheres for chemoembolization and 
holmium-polylactic acid microspheres for radio 
embolization proved to be promising candidates for the 
embolization of head and neck cancer. Particles with a 
mean diameter of at least 40 mm and volume weight mean 
size up to 70 mm are preferably used for the embolization 
of head and neck cancer. 
4.1.5 Spleen tumors 
Spleen imaging illustrates anatomic changes in the 
spleen and radiocolloids have been successfully used for the 
purpose. Radio colloids get concentrated in splenic tissues 
by phagocytosis. Therefore by spleen scanning we can 
depict the size, shape and position of the splenic tissue. 
Conventional splenic embolization with radio labeled 
microspheres was introduced as an alternative to 
splenectomy. Hypersplenism is characterized by 
inappropriate sequestration and destruction of blood 
elements and results in a diminished number of circulating 
thrombocytes or RBCs, WBCs. Hypersplenism may occur 
in patients with a variety of haematologic, inflammatory, 
metabolic and neoplastic disorders. Many patients with 
hypersplenism have an increased risk at surgery. Partial 
embolization of the spleen serves as an alternative to 
surgery. In 1995 Becker et al[2] successfully used 
90
Y 
labeled microspheres (diameter 45–75 mm) in radio 
embolization of the spleen. In patients with severe 
thrombocytopenia attributable to congestive hypersplensim 
the necessary therapeutic dose was estimated to be 100 Gy 
and a computer tomography (CT) study was performed 
after radio embolization. It was found that the splenic 
volume decreased from 1400 to 470 cm
3
 and the platelet 
count increased to almost normal levels. The treatment 
showed no evidence of any complications so intraarterial 
radioembolization with 90Y resin microspheres was 
clinically effective and well tolerated in hypersplenism. 
4.1.6 Treatment of rheumatoid arthritis 
Radioisotope synovectomy (Synoviorthesis) is a 
noninvasive used for the treatment of rheumatoid arthritis. 
Radioisotope synovectomy constitutes an effective 
alternative to operative therapy. Advantages of radioisotope 
synovectomy include a simple technique, decreased or no 
hospitalization, lower costs, early and easier mobilization of 
the patients, reliable results and free of side effects. 
Radioisotope synovectomy involves the intraarticular 
injection of a radionuclide to alter or ablate the inflammed 
synovium. The treatment controls the synovial 
inflammation and maintains joint function. Upon 
administration, microspheres get uniformly distributed 
along the synovial membrane and emit beta radiation to 
fully irradiate the membrane while sparing the more distant 
joint structures [7]. Mumper et al[24] investigated poly-L-
lactic acid (PLA) microspheres containing neutron activated 
166Ho as potential agents for radionuclide synovectomy. In 
vivo retention studies were conducted by administering 
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irradiated 
166
Ho polylactic acid microspheres into the joint 
space of normal rabbits (n ¼ 6). Biodistribution data for 
166
Ho was acquired by killing the rabbits 44 h (n ¼ 1) or 
120 h (n ¼ 5) after administration of polylactic acid 
microspheres. It appeared that the majority of 
166
Ho 
leaching occurred from the joint in the first 44 h after 
administration. However no 
166
Ho activity was observed in 
the feces or lymph nodes after 120 h. The maximum soft 
tissue penetration of a beta particle emitted from 
166
Ho is 
8.4 mm. This appears ideal for the treatment of an inflamed 
knee synovium, which may become 1–7 mm thick 
depending on the severity of the disease. Thus the potential 
use of 
166
Ho in rheumatoid arthritis is very promising. In 
1998, Wang et al administered 
188
Re microspheres via intra-
articular injection in rabbits with antigen induced arthritis. 
A bio distribution study was carried out. The study revealed 
that leakage of the radiotracer from the knee was negligible. 
Ultimately 
188
Re microspheres proved to be effective 
radiopharmaceuticals for radiation synovectomy. Recently 
Wang et al conducted the histologic study to assess the 
effect of radiation synovectomy on synovium and articular 
cartilage. 
188
Re microspheres were administered into the 
knee joints of rabbits via intra-articular injection. This 
resulted in mild reactive inflammation and thrombotic 
occlusion of vessels which subsided rapidly. After 12 
weeks of injection, sclerosis of the sub synovium was 
studied. There was no significant difference in the articular 
pattern after injection of 0.3 or 0.6 mCi 
188
Re microspheres. 
It was reported that a treatment dose of 
188
Re microspheres 
caused transient inflammation of the synovium without 
causing any detectable damage to the articular cartilage of 
knee joint. The selection of the radioisotope depends upon 
the size of the joint. Usually 
90
Y and 
188
Re are used for knee 
and shoulder, 
186
Re for finger or elbow etc. The 
traditionally used radiation colloids were not ideal since 
their large size distribution led to radiation leakage from the 
joint leading to toxicity problems. The agents for potential 
use in radiation synovectomy are 
90
Y glass microspheres, 
166
Ho polylactic acid microspheres, 
188
Re human skin 
albumin microspheres. 
4.1.7 Selective internal radiation therapy (SIRT) [24-27] 
A new approach regarding the use of radioactive 
microspheres in the treatment of liver tumors and cancer is 
selective internal radiation therapy (SIRT). SIRT is another 
means of attack in the battle against liver cancer. SIRT is a 
treatment for both hepatocellular carcinoma and colorectal 
liver metastasis. It involves the delivery of millions of 
microscopic radioactive microspheres containing 
90
Y 
directly to the liver tumor. The targeted nature of SIRT 
enables the delivery of up to 40 times more radiation than 
would be possible using conventional radiotherapy. In 
Australia, approximately 200 patients have been treated in 
various phase I and phase II trials with SIRT. A phase III 
trial in Perth compared the treatment with 
fluorodeoxyuridine (FUDR) hepatic artery chemotherapy as 
the control group against the same chemotherapy plus 
SIRT. The patients who received SIRT had a better 
outcome than those treated with chemotherapy alone. 
Patients treated with SIRT showed an increase of 2 years in 
survival time from 26% to 39% and an increase of 3 years 
in survival time from 6% to 17%. SIRT targets a very high 
radiation dose to tissue in close contact with microspheres, 
but this diminishes rapidly with distance away from the 
microspheres. Thus the area close to the microspheres is 
highly effected while areas distant from the microspheres 
are spared. This is in contrast to the delivery of radiation to 
a tumor by external beam therapy where the prescribed 
dose is delivered evenly to every element of the target 
tissue. Thus SIRT causes harm only to the tumorous cells 
and is sparing the healthy hepatic cells [4]. By selective 
internal radiation therapy, established liver cancer can be 
effectively treated by the use of intrahepatic articular 
injection of 90Y resin microspheres. 25 out of 25 patients 
treated by Grady in 1979 showed good results thus leading 
to the prolongation of their life. For adjuvant therapy of 
colon cancer internal radiation therapy of the liver was done 
with phosphorous-32 colloid. 4 patients with colon cancer 
were selected. Out of 4 patients 3 did well without 
significant side effects and no evidence of liver cancer was 
found after 2 years. The fourth one died of brain metastases 
but having reduced liver cancer. Side effects of SIRT 
include post procedural fever, abdominal pain, radiation 
hepatitis and peptic ulcer. Recently in 2001, Stubbs et al. 
treated 50 patients with advanced, nonresectable colorectal 
liver metastases and a median age of 61.5 years with SIRT. 
A titrated single dose of 2.0–3.0 of 90Y microspheres was 
injected into the hepatic artery. This was followed by 
regional chemotherapy with 5-fluorouracil at four weekly 
intervals for four days by continuous infusion. Responses to 
SIRT were assessed by falling tumour markers CEA 
(Carcinoembryonic antigen) and by CT (computer 
tomography) scans. Tumour marker data suggested that 
there was a destruction of liver tumour in 90% of the 
patients by a single treatment with SIRT. Thus it was 
concluded that selective internal radiation therapy was well 
tolerated though accompanied by liver pain and nausea. 
There was no treatment related mortality in the patients. 
 
5. Future prospects [24-27] 
For radioactive microspheres more exhaustive 
search is required for the materials which are more 
biocompatible and biodegradable after the delivery of 
radioisotopes. The labeling methods are to be improved so 
that highly stable radio labeled microspheres can be 
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produced in a single, short step using a simple radio 
labeling kit. There is a need for the preparation of more 
homogenous, monosized microspheres that will allow for 
better and more reliable bio distribution results. The 
advances in molecular biology and engineering are required 
for the design of very selective and site specific therapeutic 
microspheres. Direct intra tumoral injection of radio labeled 
microspheres is a sound technique in terms of localization 
of the radiation dose, but the technique still needs further 
evaluation, particularly in terms of the safety of both the 
patient and the operating staff. Internal radiation therapy is 
likely to play a substantial role in the control of hepatic 
cancer in the near future. 
 
6. Conclusions 
Internal radionuclide therapy using radioactive 
microspheres plays a substantial role in the control of 
hepatic and other types of cancers. Radioactive 
microspheres are very stable and have a proven efficacy in 
the field of treatment of diseases especially cancer. 
Radioactive microspheres are an ideal tool for the treatment 
of diseases like rheumatoid arthritis, spleen tumors etc. 
Radioactive microspheres are able to deliver high 
concentrations of radioactivity to the target area without 
damaging normal surrounding tissue. Improvements in 
radio labeling techniques have resulted in increasingly 
stable microspheres with a leakage of less than 0.1% of the 
activity. This is the major reason of their gaining popularity 
in therapeutic applications. These radiolabeled 
microspheres serve as one of the future materials in the 
battle against cancer and tumors. Acknowledgements: We 
are grateful to University Grants Commission for providing 
us financial assistance. 
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